拓扑替康成功治疗皮下生长的人肝母细胞瘤异种移植物。

S. Warmann, J. Fuchs, L. Wilkens, K. Gratz, D. V. von Schweinitz, H. Mildenberger
{"title":"拓扑替康成功治疗皮下生长的人肝母细胞瘤异种移植物。","authors":"S. Warmann, J. Fuchs, L. Wilkens, K. Gratz, D. V. von Schweinitz, H. Mildenberger","doi":"10.1002/MPO.1228","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nHuman hepatoblastoma is an infrequent liver tumor in children. Although many hepatoblastomas can be treated adequately with well-defined treatment regimens, problems still persist with advanced and non-resectable tumors; in these cases, an effective chemotherapy is necessary to improve the patients' prognosis. This underlines the need for alternative anti-tumor agents in the treatment of human hepatoblastoma. The aim of this study was to investigate the therapeutic effects of topotecan, a water-soluble camptothecin analog (topoisomerase-I-antagonist), in an in vivo model of three human hepatoblastomas xenografted subcutaneously into nude mice.\n\n\nPROCEDURE\nHepatoblastoma cell suspensions from three children were transplanted subcutaneously into nude mice NMRI (nu/nu). Treatment with topotecan was initiated when the tumors reached a volume between 50 and 80 mm(3). A dose of 6.6 mg/kg of topotecan were given intraperitoneally every 4 days on four occasions. The tumor volume development and alpha-fetoprotein alterations were measured and statistically analyzed. After the treatment, the tumors were investigated histologically and by immunohistochemistry.\n\n\nRESULTS\nThere was a significant reduction of tumor growth in all treated tumor xenografts vs. untreated control groups (mean relative volume 3.1 vs. 47.4; P = 0,0015-0,0079). Serum alpha-fetoprotein levels were reduced in all three cell lines, in two of them significantly (mean 44,535 kU/l vs. 228,883 kU/l; P = 0.005-0.246). Histologically, the tumor necrosis rates were higher and immunohistochemistry showed lower proliferation activities in the treated tumor xenografts vs. the control groups.\n\n\nCONCLUSION\nThe data show that topotecan is an effective agent in the treatment of human hepatoblastoma xenografts. From these results, treatment with topotecan appears to be a promising alternative in the pre- and postoperative therapy of patients suffering from human hepatoblastoma","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"52 1","pages":"449-54"},"PeriodicalIF":0.0000,"publicationDate":"2001-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan.\",\"authors\":\"S. Warmann, J. Fuchs, L. Wilkens, K. Gratz, D. V. von Schweinitz, H. Mildenberger\",\"doi\":\"10.1002/MPO.1228\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\nHuman hepatoblastoma is an infrequent liver tumor in children. Although many hepatoblastomas can be treated adequately with well-defined treatment regimens, problems still persist with advanced and non-resectable tumors; in these cases, an effective chemotherapy is necessary to improve the patients' prognosis. This underlines the need for alternative anti-tumor agents in the treatment of human hepatoblastoma. The aim of this study was to investigate the therapeutic effects of topotecan, a water-soluble camptothecin analog (topoisomerase-I-antagonist), in an in vivo model of three human hepatoblastomas xenografted subcutaneously into nude mice.\\n\\n\\nPROCEDURE\\nHepatoblastoma cell suspensions from three children were transplanted subcutaneously into nude mice NMRI (nu/nu). Treatment with topotecan was initiated when the tumors reached a volume between 50 and 80 mm(3). A dose of 6.6 mg/kg of topotecan were given intraperitoneally every 4 days on four occasions. The tumor volume development and alpha-fetoprotein alterations were measured and statistically analyzed. After the treatment, the tumors were investigated histologically and by immunohistochemistry.\\n\\n\\nRESULTS\\nThere was a significant reduction of tumor growth in all treated tumor xenografts vs. untreated control groups (mean relative volume 3.1 vs. 47.4; P = 0,0015-0,0079). Serum alpha-fetoprotein levels were reduced in all three cell lines, in two of them significantly (mean 44,535 kU/l vs. 228,883 kU/l; P = 0.005-0.246). Histologically, the tumor necrosis rates were higher and immunohistochemistry showed lower proliferation activities in the treated tumor xenografts vs. the control groups.\\n\\n\\nCONCLUSION\\nThe data show that topotecan is an effective agent in the treatment of human hepatoblastoma xenografts. From these results, treatment with topotecan appears to be a promising alternative in the pre- and postoperative therapy of patients suffering from human hepatoblastoma\",\"PeriodicalId\":18531,\"journal\":{\"name\":\"Medical and pediatric oncology\",\"volume\":\"52 1\",\"pages\":\"449-54\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2001-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical and pediatric oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/MPO.1228\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical and pediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/MPO.1228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

摘要

背景:人肝母细胞瘤是儿童中一种罕见的肝脏肿瘤。尽管许多肝母细胞瘤可以通过明确的治疗方案得到充分治疗,但对于晚期和不可切除的肿瘤,问题仍然存在;在这种情况下,需要有效的化疗来改善患者的预后。这强调了在治疗人类肝母细胞瘤中需要替代的抗肿瘤药物。本研究的目的是研究拓扑替康,一种水溶性喜树碱类似物(拓扑异构酶- 1拮抗剂),在裸鼠皮下移植的三种人肝母细胞瘤的体内模型中的治疗作用。将3名儿童的肝母细胞瘤细胞悬液皮下移植到裸鼠NMRI (nu/nu)中。当肿瘤体积达到50 - 80mm时,开始使用拓扑替康治疗(3)。拓扑替康每4天腹腔注射6.6 mg/kg,共4次。测量肿瘤体积发展和甲胎蛋白变化并进行统计学分析。治疗后对肿瘤进行组织学和免疫组化检查。结果:与未治疗的对照组相比,所有治疗组的肿瘤生长均显著减少(平均相对体积3.1比47.4;P = 0.0015 - 0.0079)。血清甲胎蛋白水平在所有三种细胞系中均降低,其中两种显著降低(平均44,535 kU/l vs. 228,883 kU/l;P = 0.005-0.246)。组织学上,与对照组相比,治疗组肿瘤坏死率较高,免疫组化显示肿瘤增殖活性较低。结论拓扑替康是治疗异种人肝母细胞瘤的有效药物。从这些结果来看,拓扑替康治疗似乎是人类肝母细胞瘤患者术前和术后治疗的一个有希望的选择
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan.
BACKGROUND Human hepatoblastoma is an infrequent liver tumor in children. Although many hepatoblastomas can be treated adequately with well-defined treatment regimens, problems still persist with advanced and non-resectable tumors; in these cases, an effective chemotherapy is necessary to improve the patients' prognosis. This underlines the need for alternative anti-tumor agents in the treatment of human hepatoblastoma. The aim of this study was to investigate the therapeutic effects of topotecan, a water-soluble camptothecin analog (topoisomerase-I-antagonist), in an in vivo model of three human hepatoblastomas xenografted subcutaneously into nude mice. PROCEDURE Hepatoblastoma cell suspensions from three children were transplanted subcutaneously into nude mice NMRI (nu/nu). Treatment with topotecan was initiated when the tumors reached a volume between 50 and 80 mm(3). A dose of 6.6 mg/kg of topotecan were given intraperitoneally every 4 days on four occasions. The tumor volume development and alpha-fetoprotein alterations were measured and statistically analyzed. After the treatment, the tumors were investigated histologically and by immunohistochemistry. RESULTS There was a significant reduction of tumor growth in all treated tumor xenografts vs. untreated control groups (mean relative volume 3.1 vs. 47.4; P = 0,0015-0,0079). Serum alpha-fetoprotein levels were reduced in all three cell lines, in two of them significantly (mean 44,535 kU/l vs. 228,883 kU/l; P = 0.005-0.246). Histologically, the tumor necrosis rates were higher and immunohistochemistry showed lower proliferation activities in the treated tumor xenografts vs. the control groups. CONCLUSION The data show that topotecan is an effective agent in the treatment of human hepatoblastoma xenografts. From these results, treatment with topotecan appears to be a promising alternative in the pre- and postoperative therapy of patients suffering from human hepatoblastoma
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信